ACR Congress Review 2019

heumatoid arthritis treated with peficitinib in combination with methotrexate: a randomised, double-blind, placebo-controlled trial in Japan.
Arthritis Rheumatol. 2019; 71 (suppl 10):A507.
Takeuchi T, Tanaka Y, Sugiyama N, Iikuni N, Soma K, Shi H, Mysler E, Moots R, Smolen J, Fleischmann R. Efficacy of tofacitinib
monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with early ( ≤ 2 years) vs established ( > 2 years)
rheumatoid arthritis: a post hoc analysis of data from oral strategy. Arthritis Rheumatol. 2019; 71 (suppl 10):A1413.
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y, Chen Y, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T,
Yamada E. Longer term safety and efficacy of peficitinib in patients with rheumatoid arthritis after 22.7 months mean treatment exposure:
interim data from a long-term, open-label extension study in Japan, Korea and Taiwan. Arthritis Rheumatol. 2019; 71 (suppl 10):A508.
Taylor P, Downie B, Elboudwarej E, Hawtin R, Mirza A, Liu J. A Composite IFN-based signature is associated with a filgotinib-specific
clinical response in bDMARD-experienced rheumatoid arthritis patients. Arthritis Rheumatol. 2019; 71 (suppl 10):A2012.
Taylor P, Elboudwarej E, Downie B, Hawtin R, Liu J, Mirza A. Key inflammatory biomarkers at baseline are associated with filgotinib
response at week 12 in rheumatoid arthritis patients with inadequate response or intolerance to biologic DMARDs. Arthritis Rheumatol.
2019; 71 (suppl 10):A46.
Taylor P, Elboudwarej E, Downie B, Vestergaard L, Liu J, Mirza A, Hawtin R. bDMARD-experienced filgotinib-treated patient samples
exhibit a partial reversion to the peripheral molecular profile of a demographically matched healthy population. Arthritis Rheumatol. 2019;
71 (suppl 10):A45.
Taylor P, Pope J, Ikeda K, Zhang X, Jia B, Zhang H, Quebe A, Chen Y, Gaich C, Holzkaemper T, Cardoso A, Sebba A. Baricitinib provides
better pain relief across all disease activity levels compared with placebo and adalimumab in rheumatoid arthritis. Arthritis Rheumatol.
2019; 71 (suppl 10):A1407.
van Vollenhoven R, Östör A, Mysler E, Damjanov N, Song I, Song Y, Suboticki J, Strand V. The impact of upadacitinib versus methotrexate
or adalimumab on individual and composite disease measures in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019; 71 (suppl
10):A523.
van Vollenhoven R, Takeuchi T, Pangan A, Friedman A, Chen S, Rischmueller M, Blanco R, Xavier R, Strand V. Monotherapy with
upadacitinib in MTX-naïve patients with rheumatoid arthritis: results at 48 weeks. Arthritis Rheumatol. 2019; 71 (suppl 10):A928.
Vinet E, St-Pierre Y, Moura C, Curtis J, Bernatsky S. Serious infections in offspring exposed in utero to non-TNFi biologics and tofacitinib.
Arthritis Rheumatol. 2019; 71 (suppl 10):A1901.
Weinblatt M, Mysler E, Östör A, Broadwell A, Jeka S, Dunlap K, Suboticki J, Enejosa J, Hendrickson B, Zhong S, Cherny K, Wright G.
Impact of baseline demographics and disease activity on outcomes in patients with rheumatoid arthritis receiving upadacitinib. Arthritis
Rheumatol. 2019; 71 (suppl 10):A516.
Weinblatt M, Thomson G, Chen K, Meerwein S, Schlacher C, Cush J. Clinical responses in patients with inadequate response to
bDMARDS upon treatment with upadacitinib. Arthritis Rheumatol. 2019; 71 (suppl 10):A515.
Westhovens R, Rigby W, van der Heijde D, Ching D, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy J, Mozaffarian N, Messina O,
Landewé R, Atsumi T, Burmester G. Efficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy:
FINCH3 primary outcome results. Arthritis Rheumatol. 2019; 71 (suppl 10):A927.
Winthrop K, Genovese M, Combe B, Tanaka Y, Kivitz A, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Keystone E, Westhovens
R, Rigby W, Burmester G. Pooled safety analyses from phase 3 studies of filgotinib in patients with rheumatoid arthritis. Arthritis
Rheumatol. 2019; 71 (suppl 10):A1329.
Yamaoka K, Tanaka Y, Kameda H, Hendrickson B, Meerwein S, Zhang Y, Takeuchi T. The safety profile of upadacitinib in Japanese
patients with rheumatoid arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A2407.
*Chairman’s Pick